B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
Looney
R John
RJ
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. John_Looney@URMC.Rochester.Edu
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D011993:Recombinant Fusion Proteins; C448700:epratuzumab; D000069283:Rituximab; C511911:belimumab; C524618:TACI receptor-IgG Fc fragment fusion protein